Japanese Encephalitis: An overview of vaccine development

Order of Publishing in Issue: 
10
Volume :8
Issue :3
July, 2014
Page No: 
303-308
Authors: 
Pallichera Vijayan Shahana [1, 2] , Dipankar Das [1] , Kapil Maithal [1 *]
Address: 
[1] Indian Immunologicals Limited, Rakshapuram, Gachibowli, Hyderabad, Andhra Pradesh, 500032, India.
Address: 
[2] Department of Biotechnology, Acharya Nagarjuna University, Nagarjunanagar, Guntur, Andhra Pradesh - 522510, India

Japanese Encephalitis (JE) is a mosquito transmitted disease of pigs and humans that is caused by Japanese Encephalitis Virus (JEV). Annually around 50,000 cases are reported from Japan and other Asian countries where the disease is epidemic. But with rapid globalization and climatic shift, JEV has started to emerge in areas where the threat was previously unknown. There is no specific treatment for Japanese encephalitis and the available treatment is supportive. Vaccination is one of the most successful methods to combat infectious diseases like JE. Different vaccines for JEV have been available for many years and their use has reduced the incidence of JE in many countries. The first generation mouse brain derived vaccines are being replaced by cell culture and inactivated vaccines. The recent focus is to develop recombinant and subunit vaccines which may overcome all the side effects of the current vaccines. The present review focuses on the latest development in vaccine formulations with different approaches reported around the world.

Keywords: 
Japanese Encephalitis, Therapy.
AttachmentSize
PDF 126.94 KB

 
To download full text articles and issues in PDF at no cost.All you have to do is fill out a brief registration form. It's easy and it's free. At any time, you may request removal of your contact information from our database.
Click here to Register | Click here if you have already registered

2018 ABAP Awards

Invitation for Nominations to 2019 ABAP Awards
The Association of Biotechnology and Pharmacy invites nominations for the following awards from the eligible talented people with proven track record and achievements on or before August 31, 2019 in the prescribed format.

DOWNLOAD CIRCULAR | APPLICATION FORM

AWARDS

User login